[go: up one dir, main page]

AR065670A1 - COMBINATION OF METFORMIN R - (+) LIPOATE AND ANTIHIPERLIPIDEMIC AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLUCEMIA AND DIABETIC COMPLICATIONS - Google Patents

COMBINATION OF METFORMIN R - (+) LIPOATE AND ANTIHIPERLIPIDEMIC AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLUCEMIA AND DIABETIC COMPLICATIONS

Info

Publication number
AR065670A1
AR065670A1 ARP080100977A ARP080100977A AR065670A1 AR 065670 A1 AR065670 A1 AR 065670A1 AR P080100977 A ARP080100977 A AR P080100977A AR P080100977 A ARP080100977 A AR P080100977A AR 065670 A1 AR065670 A1 AR 065670A1
Authority
AR
Argentina
Prior art keywords
diabetic
lipoate
metformin
treatment
pharmaceutical composition
Prior art date
Application number
ARP080100977A
Other languages
Spanish (es)
Original Assignee
Indigene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indigene Pharmaceuticals Inc filed Critical Indigene Pharmaceuticals Inc
Publication of AR065670A1 publication Critical patent/AR065670A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones farmacéuticas, métodos y kits, que comprenden metformina R-(+) lipoato y un agente antihiperlipidémico o una sal, hidrato, solvato y prodroga derivada de la misma farmacéuticamente aceptable para el tratamiento de hiperglucemiadiabética Tipo 2 y las complicaciones diabéticas. Reivindicacion 1: Una composicion farmacéutica caracterizada porque comprende metformina R-(+) lipoato [MR-(+)LA], y un inhibidor reductasa HMG-CoA o una sal aceptable en términos farmacéuticos,hidrato, solvato o un profármaco derivado de estos. Reivindicacion 7: La composicion farmacéutica de la reivindicacion 4 caracterizada porque el inhibidor reductasa HMG-CoA es atorvastatina cálcica. Reivindicacion 14: La composicion farmacéuticade la reivindicacion 3 caracterizada porque el inhibidor reductasa HMG-CoA es simvastatina, o una sal de esta aceptable en términos farmacéuticos. Reivindicacion 23: La composicion farmacéutica de la reivindicacion 22, caracterizada porque elinhibidor de absorcion de colesterol es ezetimibe, o una sal aceptable en términos farmacéuticos, hidrato, solvato y un profármaco derivado de éste.Pharmaceutical compositions, methods and kits, comprising metformin R - (+) lipoate and an antihyperlipidemic agent or a pharmaceutically acceptable salt, hydrate, solvate and prodrug thereof for the treatment of Type 2 hyperglycemia and diabetic complications. Claim 1: A pharmaceutical composition characterized in that it comprises metformin R - (+) lipoate [MR - (+) LA], and an HMG-CoA reductase inhibitor or an acceptable salt in pharmaceutical terms, hydrate, solvate or a prodrug derived therefrom. Claim 7: The pharmaceutical composition of claim 4 characterized in that the HMG-CoA reductase inhibitor is calcium atorvastatin. Claim 14: The pharmaceutical composition of claim 3 characterized in that the HMG-CoA reductase inhibitor is simvastatin, or a salt thereof is acceptable in pharmaceutical terms. Claim 23: The pharmaceutical composition of claim 22, characterized in that the cholesterol absorption inhibitor is ezetimibe, or a pharmaceutically acceptable salt, hydrate, solvate and a prodrug derived therefrom.

ARP080100977A 2007-03-09 2008-03-07 COMBINATION OF METFORMIN R - (+) LIPOATE AND ANTIHIPERLIPIDEMIC AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLUCEMIA AND DIABETIC COMPLICATIONS AR065670A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90599007P 2007-03-09 2007-03-09

Publications (1)

Publication Number Publication Date
AR065670A1 true AR065670A1 (en) 2009-06-24

Family

ID=39760278

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100977A AR065670A1 (en) 2007-03-09 2008-03-07 COMBINATION OF METFORMIN R - (+) LIPOATE AND ANTIHIPERLIPIDEMIC AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLUCEMIA AND DIABETIC COMPLICATIONS

Country Status (5)

Country Link
EP (1) EP2134169A2 (en)
AR (1) AR065670A1 (en)
CL (1) CL2008000684A1 (en)
TW (1) TW200901959A (en)
WO (1) WO2008112166A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085223A1 (en) * 2007-12-20 2009-07-09 Indigene Pharmaceuticals, Inc. Combination of metformin r-(+)-lipoate and antihyperglycemic agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2012073256A1 (en) * 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin
WO2015001568A2 (en) * 2013-07-01 2015-01-08 Laurus Labs Private Limited Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof
WO2015183794A1 (en) * 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
WO2020041799A1 (en) * 2018-08-24 2020-02-27 Esperion Therapeutics, Inc. Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2513251A (en) 1947-06-21 1950-06-27 Allied Chem & Dye Corp Preparation of pyridine carboxylic acids
GB860303A (en) 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3308020A (en) 1961-09-22 1967-03-07 Merck & Co Inc Compositions and method for binding bile acids in vivo including hypocholesteremics
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
FI52570C (en) 1969-04-16 1977-10-10 Sumitomo Chemical Co Process for producing the cholesterol or lipoid content of the blood using phenoxyaliphatic carboxylic acid compounds and ester compounds.
US3692895A (en) 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
DE2230383C3 (en) 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarboxylic acid derivatives and processes for making the same
US3948973A (en) 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
US4205064A (en) 1973-06-11 1980-05-27 Merck & Co., Inc. Bile acid sequestering composition containing poly[{alkyl-(3-ammoniopropyl)imino}-trimethylenedihalides]
JPS5612114B2 (en) 1974-06-07 1981-03-18
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
ES8101585A1 (en) 1980-02-15 1980-12-16 Especialidades Farmaco Terape Glyceryl 2-para-chloro:phenoxy-isobutyrate-1,3-di:nicotinate - hypolipaemic and hypocholesterolaemic used to treat atherosclerosis, hyperlipoproteinaemia and high tri:glyceride plasma levels
MX7065E (en) 1980-06-06 1987-04-10 Sankyo Co A MICROBIOLOGICAL PROCEDURE FOR PREPARING DERIVATIVES OF ML-236B
US4367234A (en) 1980-07-28 1983-01-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4342771A (en) 1981-01-02 1982-08-03 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4617312A (en) 1983-01-17 1986-10-14 Pfizer Inc. Aldose reductase inhibiting 5-(2-alkoxyphenyl) thiazolidinediones
AR240698A1 (en) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts
US4703052A (en) 1985-05-21 1987-10-27 Pfizer Inc. Hypoglycemic thiazolidinediones
US4895723A (en) 1986-09-08 1990-01-23 Amer And Company Cholestyramine compositions and method for preparation thereof
JP2569746B2 (en) 1987-08-20 1997-01-08 日産化学工業株式会社 Quinoline mevalonolactones
US5268181A (en) 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US5126145A (en) 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
EP0508425A1 (en) 1991-04-12 1992-10-14 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
DK0637297T3 (en) 1992-04-22 2000-09-18 Ligand Pharm Inc Compounds having selectivity for retinoid X receptors
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
ES2217392T3 (en) 1996-02-02 2004-11-01 MERCK & CO., INC. ANTIDIABETIC AGENTS.
CA2244831A1 (en) 1996-02-02 1997-08-07 John T. Olson Method of treating diabetes and related disease states
JP2002503202A (en) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド Antidiabetic drugs
WO1997028137A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents
US6203785B1 (en) 1996-12-30 2001-03-20 Geltex Pharmaceuticals, Inc. Poly(diallylamine)-based bile acid sequestrants
US6469035B1 (en) 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
TW438784B (en) 1997-08-29 2001-06-07 Ssp Co Ltd Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6294163B1 (en) 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
US6271264B1 (en) 1998-12-01 2001-08-07 Geltex Pharmaceuticals, Inc. Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants
US6190649B1 (en) 1999-04-23 2001-02-20 Geltex Pharmaceuticals, Inc. Polyether-based bile acid sequestrants
FR2796551B1 (en) 1999-07-23 2003-07-25 Lipha NOVEL METFORMIN SALTS, PROCESS FOR OBTAINING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
CO5271716A1 (en) 1999-11-30 2003-04-30 Pfizer Prod Inc CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACED
HN2000000203A (en) 1999-11-30 2001-06-13 Pfizer Prod Inc PROCEDURE FOR OBTAINING 1,2,3,4-TETRAHYDROQUINOLINS 4-CARBOXYAMIN-2-SUBSTITUTED.
IL152179A (en) 2000-04-10 2009-06-15 Teva Pharma Stable pharmaceutical compositions containing 7-substituted-3,5- dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
WO2002036563A1 (en) 2000-10-31 2002-05-10 Ciba Specialty Chemicals Holding Inc. Crystalline forms of fluvastatin sodium
EP1345903A1 (en) 2000-12-21 2003-09-24 Ciba SC Holding AG Crystalline forms of cerivastatin sodium
SI20848A (en) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Pharmaceutical formulation containing atorvastatin calcium
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
CA2445693A1 (en) 2001-04-30 2002-11-07 Pfizer Products Inc. Compounds useful as intermediates for 4-aminoquinoline derivatives
US20030220301A1 (en) * 2002-02-14 2003-11-27 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
WO2004050037A2 (en) 2002-12-04 2004-06-17 Agennix Incorporated Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
TW200500362A (en) * 2003-04-09 2005-01-01 Japan Tobacco Inc 5-membered heteroaromatic ring compound and pharmaceutical use thereof
RU2005137865A (en) * 2003-06-06 2006-06-10 Такеда Фармасьютикал Компани Лимитед (Jp) SOLID PREPARATION
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives

Also Published As

Publication number Publication date
TW200901959A (en) 2009-01-16
WO2008112166A3 (en) 2008-10-30
WO2008112166A2 (en) 2008-09-18
CL2008000684A1 (en) 2008-08-01
EP2134169A2 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
AR067030A2 (en) PHARMACEUTICAL COMPOSITIONS
GT200500278A (en) FUNGICIDE COMPOSITIONS
UY29983A1 (en) DERIVATIVES OF 4-AMINO-PIRROLOTRIAZINE REPLACED USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
ECSP077980A (en) AKT ACTIVITY INHIBITORS
GT200800184A (en) AMINOTETRAHYDROPIRANS AS INHIBITORS OF DIPEPTIDIL PEPTIDASA-IV FOR THE TREATMENT OR PREVENTION OF DIABETES.
ATE428411T1 (en) HDL-BOOSTING COMBINATION THERAPY COMPLEXES
CL2009001059A1 (en) Compounds derived from substituted 1,3-oxazin-2-one-3.6, inhibitors of the activity of 11-beta-hydroxysteroid dehydrogenase i; pharmaceutical composition that includes them; Useful in the treatment of diseases such as diabetes mellitus, among others.
BRPI0717907A2 (en) "COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING A CANCER, INHIBITING OR MODULATING LIPID KINASE ACTIVITY, PROCESS FOR PRODUCING PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND AND KIT"
EA200900821A1 (en) DERIVATIVES 1-AMINOMETHIL-L-PHENYLCICLOGEXANE AS DPP-IV INHIBITORS (DIPEPTIDYLPEPTIDASE-IV)
WO2006119283A3 (en) Anti-odor compositions and therapeutic use
AR065670A1 (en) COMBINATION OF METFORMIN R - (+) LIPOATE AND ANTIHIPERLIPIDEMIC AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLUCEMIA AND DIABETIC COMPLICATIONS
ECSP099483A (en) COMBINATION OF A HISTONE DEACETILASE INHIBITOR AND AN ANTIMETABOLITE
PA8627601A1 (en) HYDROCLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) -PIPERIDIN-1-ILO] - (4-BROMO-3-METHYL-5-PROPOXI-TIOFEN-2-ILO) -METANONE HYDROCLORIDE AS AN INHIBITOR OF MASTOCYT TRIPTASE
NO20090234L (en) Tricyclic composition and pharmaceutical use thereof
BRPI0515261A (en) compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, use of the chemical compound or any of its isomers or any mixture of isomers thereof, or a pharmaceutically acceptable salt thereof, and a method for treating, preventing or relief from a disease or disorder or condition of a living animal body
AR039664A1 (en) PHARMACEUTICAL COMPOSITION INCLUDED BY A LIPASE AND GLUCOMANAN INHIBITOR
EA200702282A1 (en) COMBINATION OF FERROHIN AND DERIVATIVE ARTEMIZININ FOR THE TREATMENT OF MALARIA
CR9521A (en) NEW METHOD OF TREATMENT OF HYPERLIPEDEMIA
ECSP10010381A (en) ASSOCIATION BETWEEN A BIS-TIAZOLIO SALT OR ONE OF ITS PRECURSORS AND ARTEMISININE OR ONE OF ITS DERIVATIVES FOR THE TREATMENT OF SERIOUS PALUDISM
ECSP078015A (en) 4-ANILINO-3-QUINOLINOCARBONITRILOS FOR THE TREATMENT OF CANCER
BRPI0507859A (en) use of cholinesterase inhibitors
AR065070A1 (en) ATORVASTATIN ESTRONIC SALT AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
BRPI0519006A2 (en) use of a fbpase inhibitor, kit of a pharmaceutical composition, use of a biguanide preparation and a fbpase inhibitor, therapeutic agent for diabetes mellitus, and combination of therapeutic agents
BRPI0704121A (en) synergistically antimicrobial composition
AR048668A1 (en) HYPOOCOLESTEROLEMIANT COMPOSITIONS AND PROCEDURE TO PREPARE THEM

Legal Events

Date Code Title Description
FB Suspension of granting procedure